It seems only those at high risk for stroke and at low risk for the adverse effects of aspirin (i.e., gastrointestinal bleeding and hemorrhagic stroke), according to the results of a recent cost-utility analysis.
It seems only those at high risk for stroke and at low risk for the adverse effects of aspirin (i.e., gastrointestinal bleeding and hemorrhagic stroke), according to the results of a recent cost-utility analysis.
Researchers determined that aspirin costs $13,300 per quality-adjusted life-year (QALY) gained in 65-year-old women with a moderate 10-year cardiovascular risk and that in these moderate-risk women, there is a 27% chance that aspirin will be less effective than no treatment.
Based on the results, preventive aspirin therapy is probably not appropriate for women at lower risk, including women 55 years and younger without additional stroke risk factors.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More